F-star Therapeutics Inc.

6.27+0.0200+0.32%Vol 38.26K1Y Perf -14.50%
Oct 5th, 2022 16:00 DELAYED
BID6.25 ASK6.35
Open6.16 Previous Close6.25
Pre-Market- After-Market-
 - -%  - -
Target Price
7.00 
Analyst Rating
Hold 3.00
Potential %
11.64 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/-100 
Value Ranking
★★     46.62
Insiders Value % 3/6/12 mo.
-/-/-100 
Growth Ranking
+     33.24
Insiders Shares Cnt. % 3/6/12 mo.
-/-/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
76.78 
Earnings Rating
Market Cap135.33M 
Earnings Date
9th Nov 2022
Alpha-0.01 Standard Deviation0.27
Beta1.02 

Today's Price Range

6.150.00

52W Range

2.077.54

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
24.16%
1 Month
0.16%
3 Months
0.16%
6 Months
76.62%
1 Year
-14.50%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
FSTX6.270.02000.32
AAPL146.400.30000.21
GOOG102.22-0.1900-0.19
MSFT249.200.32000.13
XOM99.123.85004.04
WFC43.31-0.2300-0.53
JNJ165.11-0.5100-0.31
FB196.640.99000.51
GE67.44-0.1000-0.15
JPM110.39-1.3800-1.23
 
ProfitabilityValueIndustryS&P 500US Markets
-
-175.00
-171.70
-
-91.58
RevenueValueIndustryS&P 500US Markets
20.05M
0.93
-
-
Earnings HistoryEstimateReportedSurprise %
Q02 2022-0.62-0.88-41.94
Q01 2022-0.63-0.579.52
Q04 2021-0.430.47209.30
Q03 2021-0.56-0.527.14
Q02 2021-0.77-0.92-19.48
Q01 2021-1.26-1.0814.29
Q02 2020-1.44-1.52-5.56
Q01 2020-0.80-1.96-145.00
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date9th Nov 2022
Estimated EPS Next Report-0.67
Estimates Count4
EPS Growth Next 5 Years %-
Volume Overview
Volume38.26K
Shares Outstanding21.58K
Shares Float21.35M
Trades Count457
Dollar Volume239.91K
Avg. Volume230.42K
Avg. Weekly Volume273.03K
Avg. Monthly Volume216.90K
Avg. Quarterly Volume201.35K

F-star Therapeutics Inc. (NASDAQ: FSTX) stock closed at 6.27 per share at the end of the most recent trading day (a 0.32% change compared to the prior day closing price) with a volume of 38.26K shares and market capitalization of 135.33M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 79 people. F-star Therapeutics Inc. CEO is Eliot Richard Forster.

The one-year performance of F-star Therapeutics Inc. stock is -14.5%, while year-to-date (YTD) performance is 24.9%. FSTX stock has a five-year performance of %. Its 52-week range is between 2.07 and 7.54, which gives FSTX stock a 52-week price range ratio of 76.78%

F-star Therapeutics Inc. currently has a PE ratio of -3.40, a price-to-book (PB) ratio of 1.54, a price-to-sale (PS) ratio of 6.71, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -35.18%, a ROC of -36.40% and a ROE of -46.67%. The company’s profit margin is -91.58%, its EBITDA margin is -171.70%, and its revenue ttm is $20.05 Million , which makes it $0.93 revenue per share.

Of the last four earnings reports from F-star Therapeutics Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.67 for the next earnings report. F-star Therapeutics Inc.’s next earnings report date is 09th Nov 2022.

The consensus rating of Wall Street analysts for F-star Therapeutics Inc. is Hold (3), with a target price of $7, which is +11.64% compared to the current price. The earnings rating for F-star Therapeutics Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

F-star Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

F-star Therapeutics Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 58.87, ATR14 : 0.33, CCI20 : 49.93, Chaikin Money Flow : -0.25, MACD : -0.14, Money Flow Index : 43.18, ROC : 8.10, RSI : 65.34, STOCH (14,3) : 87.50, STOCH RSI : 1.00, UO : 51.49, Williams %R : -12.50), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of F-star Therapeutics Inc. in the last 12-months were: Louis Kayitalire (Sold 64 shares of value $437 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0 (0.00 %)
0 (0.00 %)
1 (25.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
4 (100.00 %)
4 (100.00 %)
3 (75.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingHold
3.00
Hold
3.00
Moderate Buy
2.50

F-star Therapeutics Inc.

F-star Therapeutics Inc is a clinical-stage biopharmaceutical company developing tetravalent bispecific antibodies for a paradigm-shift in cancer therapy. By developing medicines that seek to block tumor immune evasion, the company's goal is to offer patients greater and more durable benefits than immuno-oncology treatments.

CEO: Eliot Richard Forster

Telephone: +44 1223497400

Address: Babraham Research Campus, Cambridge CB22 3AT, , GB

Number of employees: 79

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

53%47%

Bearish Bullish

49%51%

Bearish Bullish

51%49%


News

Stocktwits